Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Rivaroxaban for thromboprophylaxis in high-risk cancer patients: CASSINI results

Alok Khorana • 6 Dec 2018
ASH 2018
General Rivaroxaban
CASSINI

The CASSINI trial investigated the use of rivaroxaban to prevent the development of blood clots in high-risk ambulatory cancer patients receiving systemic therapy. Alok Khorana, MD, of the Cleveland Clinic, Cleveland, OH, presents the data at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Alok Khorana

2:31
CASSINI: can we prevent thrombosis in cancer patients who are at risk?
Alok Khorana • 6 Dec 2018
0:40
VTE in cancer patients treated with immunotherapy
Alok Khorana • 3 Dec 2018

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals